Antiviral and immune therapy

SCS

Antiviral and immune therapy SCS12

Auditorium 1 - Plenary Hall

Chairs

Adolfo GARCÍA-SASTRE

Icahn School of Medicine at Mount Sinai, United States

Josefine SCHROEDER

Jena University Hospital, Germany

Effectiveness of the approved antiviral drugs for mild/moderate infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Hong Kong

George OKOLIThe University of Hong Kong, Hong Kong SAR China
Impact of Antiviral Timing and Vaccination on Viral Shedding in Hospitalized Older Adults with COVID-19 During Omicron Predominance

Yun LINWorld Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China, Hong Kong SAR China
Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase

Bahaaeldin ALHAMMADYLeibniz-Institut für Virologie (LIV), Germany
Treatment with pictilisib-loaded lipid nanoparticles reduces influenza A virus infection in vitro and ex vivo

Josefine SCHROEDERJena University Hospital, Germany
Comparative assessment of in vivo antiviral activity of anti-influenza drugs (AD ASTRA)

Podjanee JITTAMALAMahidol University, Thailand